Opinions
Fabrice Taylor
Helius Medical Technologies
HSM-T
RISKY
Dec 02, 2016
Stock price when the opinion was issued
You might be interested:
(A Top Pick April 27/16. Up 31%.) Still very bullish on this. Makes a medical device that can help with traumatic brain injuries, along with other things. They are close to sending in data to FDA on a traumatic brain injury study. Thinks the stock is going to start to move as we get closer to that date. It looks like this could be an “over-the-counter” product for consumers.
He thinks there is going to be a run up, because often times in Biotech’s you get a run into the news, so he thinks it will do well as we get closer to the big announcements, regardless of what the outcome is. The downside has been mitigated by the fact that it could be a consumer business. (Analysts’ price target is $2.34.)
They make a device that is being tested to treat traumatic brain injury including a lot of soldiers in the US. Results should be out in September. Data is what gets people excited. If it is good and early signs are good. Then they go into FDA approval and the stock multiplies in price. It is high risk, but he thinks you will see enthusiasm in September. He is confident they will get FDA approval. The military really needs this to happen for all their wounded soldiers.
A medical device that helps brain injury, as well as the potential to help with other diseases. He started recommending this at about $1.25, and it doubled in about a year, and he added more to his holdings. At this point, he has his original money out, but still owns a lot. Feels it has a lot of potential. It looks like FDA approval is a given and the data is coming out in a couple of weeks.
They put out some numbers from their trial that the one analyst covering it who called the trial a failure. The company doesn't agree, and there was a lot of confusion. The group getting the actual treatment showed a 75% result but the sham group had a 60% result. As It's an electrical current, they had to give the control group some electrical current otherwise they would know. The company felt that was great news as it showed that the device worked even at a lower frequency. It enhances physiotherapy for people who have motor issuws. There is more data coming out and in a year we will know more.
(A Top Pick May 30, 2017. Up 8%). These are exciting times for the company. They are going through FDA approval. He believes that it will be approved because the device has low risk and addresses an unmet need. The stock was recently $25 a share, and he thinks it will rise to $50 if everything works out as planned.
A biotech company. Speculative because they don’t have any revenues yet. They are testing out a device called The Pons, which has been shown to improve a recovery rate in people that have traumatic brain injuries and illnesses like MS. In FDA trials right now. What makes it interesting is that it is in an unmet need.